Epoprostenol and Prostaglandin share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.133 means 13% of the combined target set is bound by both compounds. The IDF-weighted score of 0.157 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Epoprostenol and Prostaglandin have in common?
Epoprostenol and Prostaglandin share 2 molecular targets with a Jaccard similarity of 13%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Epoprostenol and Prostaglandin be combined?
Epoprostenol and Prostaglandin share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Epoprostenol or Prostaglandin?
Both Epoprostenol and Prostaglandin have substantial PubMed research. View their individual profiles for full evidence scores.